EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetic model of tranexamic acid in patients who undergo cardiac surgery with cardiopulmonary bypass

Tsuyoshi Nakai, Takahiro Tamura, Yasuhiro Miyagawa, Takayuki Inagaki, Masato Mutsuga, Shigeki Yamada, Kiyofumi Yamada, Kimitoshi Nishiwaki, Hiroyuki Mizoguchi

European Journal of Clinical Pharmacology · 2025-03 · 81 (3) · 441-449

DOI: 10.1007/s00228-025-03802-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 16.01.2025. Verfasst von Tsuyoshi Nakai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 4…. Hauptthemen laut MEDLINE: Tranexamic Acid, Cardiopulmonary Bypass, Antifibrinolytic Agents, Cardiac Surgical Procedures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI Grant, Nagoya University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tranexamic acid (TXA) is widely used as an antifibrinolytic drug. However, studies to determine the optimal blood concentration of TXA have produced inconsistent results. During cardiac surgery, cardiopulmonary bypass (CPB) has serious effects on drug distribution, elimination, and plasma concentration. Therefore, we aimed to establish a population pharmacokinetics model of TXA in patients undergoing cardiac surgery with CPB that considers renal function as a covariate, thereby facilitating personalized treatment.

Methods

In total, 453 TXA plasma samples were prospectively collected from 77 patients who underwent cardiac surgery with CPB. Plasma concentrations were determined by ultra-performance liquid chromatography-tandem mass spectrometry. The population pharmacokinetic model of TXA was analyzed using nonlinear mixed-effects modeling.

Results

The two-compartment–based model with combined errors was determined as the best. The final model included the effect of bodyweight and CL cr may be summarized as V 1 (L) = 12.77 × (bodyweight / 61.4) 0.911 , V 2 (L) = 6.857, CL 1 (L/h) = 3.263 × [CL cr (L/h) / 61.0] 0.752 , CL 2 (L/h) = 2.859.

Conclusion

Patients who undergo cardiac surgery with CPB may require an adjusted dose of TXA tailored to CPB due to lower CL 1 and increased V 1 . Our TXA population pharmacokinetic model may be useful for developing individualized dosing designs for TXA in patients who undergo cardiac surgery with CPB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidCardiopulmonary BypassAntifibrinolytic AgentsCardiac Surgical ProceduresModels, BiologicalHumansMaleFemaleAgedMiddle AgedAdultProspective StudiesAged, 80 and over

Stichwörter der Autor:innen

Cardiac surgeryCardiopulmonary bypassPopulation pharmacokineticTranexamic acid

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan. tsuyoshi.nakai@fujita-hu.ac.jp.
  • Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan. tsuyoshi.nakai@fujita-hu.ac.jp.
  • Department of Anesthesiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
  • Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan. miyagawa.yasuhiro.x0@f.mail.nagoya-u.ac.jp.
  • Division of Pharmaceutical Sciences I, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-Ku, Nagoya, 468-8503, Japan.
  • Department of Cardiac Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI Grant
  • Nagoya University

Zitieren

APA

Nakai, T., Tamura, T., Miyagawa, Y., Inagaki, T., Mutsuga, M., Yamada, S., Yamada, K., Nishiwaki, K., & Mizoguchi, H. (2025). Population pharmacokinetic model of tranexamic acid in patients who undergo cardiac surgery with cardiopulmonary bypass. European Journal of Clinical Pharmacology, 81(3), 441-449. https://doi.org/10.1007/s00228-025-03802-0

Vancouver

Nakai T, Tamura T, Miyagawa Y, Inagaki T, Mutsuga M, Yamada S, et al. Population pharmacokinetic model of tranexamic acid in patients who undergo cardiac surgery with cardiopulmonary bypass. European Journal of Clinical Pharmacology. 2025;81(3):441-449. doi:10.1007/s00228-025-03802-0

BibTeX
@article{Nakai2025,
  author = {Nakai, Tsuyoshi and Tamura, Takahiro and Miyagawa, Yasuhiro and Inagaki, Takayuki and Mutsuga, Masato and Yamada, Shigeki and Yamada, Kiyofumi and Nishiwaki, Kimitoshi and Mizoguchi, Hiroyuki},
  title = {Population pharmacokinetic model of tranexamic acid in patients who undergo cardiac surgery with cardiopulmonary bypass},
  journal = {European Journal of Clinical Pharmacology},
  year = {2025},
  volume = {81},
  number = {3},
  pages = {441--449},
  doi = {10.1007/s00228-025-03802-0}
}
Kostenlos starten →